2021年3⽉期 第1四半期 決算参考資料
Financial Data for the 1st quarter of FY2021
The FY2021, the year ending March 31, 2021
April 1, 2020 - March 31, 2021 | |||
1. | 連結決算概要 / Consolidated Financial Summary | 2 | |
2. | セグメント別情報 / Information by Business Segment | 3,4 | |
(1) | 医療事業 / Medical Business | ||
ESD (Endoscopic Solutions Division)・TSD (Therapeutic Solutions Division) | 5 | ||
(2) | 科学事業 / Scientific Solutions Division | ||
(3) | 映像事業 / Imaging Division | 6 | |
(4) | その他 / Others | 7 | |
(5) | 全社消去 / Corporate Expenses | 7 | |
3. | 連結財政状態計算書 / Statement of Financial Position | 8 | |
4. | キャッシュフロー計算書 / Statement of Cash Flows | 8 | |
5. | 指標 / Financial Indicators | 9 | |
6. | 会社概要 / Corporate Outline | 10 | |
(付録 / Appendix) | 11,12 | ||
7. | オリンパスの医療事業 / Medical Business of Olympus |
(本資料における留意点について)
(Notes regarding this material)
・本資料のうち、業績⾒通し等は、現在⼊⼿可能な情報による判断および仮定に基づいたものであり、判断や仮定に内在 する不確定な要素および今後の事業運営や内外の状況変化等による変動可能性に照らし、実際の業績等が⽬標と⼤き く異なる可能性があります。
・また、これらの情報は、今後予告なしに変更されることがあります。従いまして、本情報及び資料の利⽤は、他の⽅法によ り⼊⼿された情報とも照合確認し、利⽤者の判断によって⾏ってくださいますようお願い致します。
・本資料利⽤の結果⽣じたいかなる損害についても、当社は⼀切責任を負いません。
・This material contains forward-looking statements that reflect managementʼs current views, plans, and expectations based on information available at the time of preparation. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, future business decisions, and other internal and external factors that may cause the Companyʼs actual results, performance, achievements, or financial position to be materially different from any future results expressed or implied by these forward-looking statements.
・Additionally, this information is subject to change without notice. Accordingly, other information should be used in addition to this material when making investment decisions.
・Olympus Corporation assumes no responsibility for any damage resulting from the use of this material.
1.連結決算概要 / Consolidated Financial Summary | |||||||||||
■連結損益計算書概要 / Summary of Consolidated Statements of Profit or Loss | 百万円( million) | ||||||||||
項⽬ | FY2020 | FY2021 | |||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | |
売上⾼ | 181,885 | 207,304 | 205,882 | 202,340 | 797,411 | 142,403 | - | - | - | - | |
Revenue | |||||||||||
売上原価 | 65,175 | 73,353 | 75,597 | 83,719 | 297,844 | 55,149 | - | - | - | - | |
Cost of sales | |||||||||||
売上総利益 | 116,710 | 133,951 | 130,285 | 118,621 | 499,567 | 87,254 | - | - | - | - | |
Gross profit | |||||||||||
販売費及び⼀般管理費 | 101,074 | 95,638 | 99,653 | 108,658 | 405,023 | 84,634 | - | - | - | - | |
S.G.A. expenses | |||||||||||
その他の収益および費⽤等 | -900 | -2,112 | -3,084 | -4,979 | -11,075 | -1,430 | - | - | - | - | |
Other income and expenses etc. | |||||||||||
営業利益 | 14,736 | 36,201 | 27,548 | 4,984 | 83,469 | 1,190 | - | - | - | - | |
Operating profit | |||||||||||
⾦融収益および費⽤ | -1,129 | -1,239 | -1,926 | -1,377 | -5,671 | -981 | - | - | - | - | |
Finance income and costs | |||||||||||
税引前利益 | 13,607 | 34,962 | 25,622 | 3,607 | 77,798 | 209 | - | - | - | - | |
Profit before tax | |||||||||||
法⼈所得税費⽤ | 4,964 | 7,541 | 2,545 | 11,093 | 26,143 | 2,941 | - | - | - | - | |
Income taxes | |||||||||||
当期利益 | 8,643 | 27,421 | 23,077 | -7,486 | 51,655 | -2,732 | - | - | - | - | |
Profit | |||||||||||
親会社の所有者に帰属する当期利益 | 8,637 | 27,426 | 23,075 | -7,468 | 51,670 | -2,736 | - | - | - | - | |
Profit attributable to owners of parent | |||||||||||
売上総利益率 | 64.2% | 64.6% | 63.3% | 58.6% | 62.6% | 61.3% | - | - | - | - | |
Gross profit ratio | |||||||||||
販管費率 | 55.6% | 46.1% | 48.4% | 53.7% | 50.8% | 59.4% | - | - | - | - | |
S.G.A. ratio | |||||||||||
営業利益率 | 8.1% | 17.5% | 13.4% | 2.5% | 10.5% | 0.8% | - | - | - | - | |
Operating profit margin | |||||||||||
当期利益率 | 4.7% | 13.2% | 11.2% | -3.7% | 6.5% | -1.9% | - | - | - | - | |
Profit margin | |||||||||||
ROE | - | - | - | - | 12.7% | - | - | - | - | - | |
EBITDA | 32,163 | 52,172 | 44,674 | 22,769 | 151,778 | 16,568 | - | - | - | - | |
EBITDAマージン | 17.7% | 25.2% | 21.7% | 11.3% | 19.0% | 11.6% | - | - | - | - | |
EBITDA margin | |||||||||||
■投資他 / Expenditures etc | 百万円( million) | ||||||||||
項⽬ | FY2020 | FY2021 | |||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | |
減価償却費 | 17,427 | 15,971 | 17,126 | 17,785 | 68,309 | 15,378 | - | - | - | - | |
Depreciation and amortization | |||||||||||
資本的⽀出 | 14,623 | 18,236 | 16,933 | 27,392 | 77,184 | 15,359 | - | - | - | - | |
Capital expenditures | |||||||||||
研究開発⽀出 | 21,195 | 23,624 | 22,157 | 24,613 | 91,589 | 18,694 | - | - | - | - | |
R&D expenditures | |||||||||||
開発費資産化 | 3,329 | 5,047 | 6,009 | 8,619 | 23,004 | 3,415 | - | - | - | - | |
Capitalization of R&D expenditures | |||||||||||
■為替 / Foreign exchange | |||||||||||
項⽬ | FY2020 | FY2021 | |||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | |
円/USD(期中平均レート) | 109.90 | 107.35 | 108.76 | 108.92 | 108.74 | 107.62 | - | - | - | - | |
Yen/U.S. dollar (Average rate) | |||||||||||
円/EUR(期中平均レート) | 123.49 | 119.34 | 120.32 | 120.11 | 120.82 | 118.48 | - | - | - | - | |
Yen/Euro (Average rate) | |||||||||||
円/CNY(期中平均レート) | 16.07 | 15.29 | 15.45 | 15.60 | 15.60 | 15.17 | - | - | - | - | |
Yen/Renminyuan (Average rate) | |||||||||||
売上⾼に対する為替影響額 | -3,843 | -9,559 | -8,538 | -4,719 | -26,659 | -5,381 | - | - | - | - | |
FX Impact on revenue | |||||||||||
営業利益に対する為替影響額 | -734 | -3,588 | -3,996 | -2,132 | -10,450 | -1,732 | - | - | - | - | |
FX Impact on operating profit | |||||||||||
■為替感応度(年間) / Foreign exchange sensitivity (Annual basis) | 億円 ( 100 million) | ||||||||||
項⽬ | 売上⾼ | 営業利益 | |||||||||
Item | Revenue | Operating profit | |||||||||
ドル(1円あたり) | 26 | 9 | |||||||||
U.S. dollar(Per 1JPY) | |||||||||||
ユーロ(1円あたり) | 17 | 7 | |||||||||
Euro(Per 1JPY) | |||||||||||
⼈⺠元(1円あたり) | 59 | 40 | |||||||||
Renminyuan(Per 1JPY) | |||||||||||
■従業員数 / Number of employees | |||||||||||
項⽬ | FY2020 | FY2021 | |||||||||
Item | As of Mar 31 | As of Jun 30 | As of Sep 30 | As of Dec 31 | As of Mar 31 | ||||||
連結 | 35,174 | (21,571) | 34,955 | (20,916) | - | - | - | - | - | - | |
Consolidated | |||||||||||
内視鏡事業 | 14,013 | (7,781) | 14,039 | (7,688) | - | - | - | - | - | - | |
Endoscopic Solutions Division | |||||||||||
治療機器事業 | 6,888 | (4,801) | 7,268 | (4,771) | - | - | - | - | - | - | |
Therapeutic Solutions Division | |||||||||||
医療事業 | 20,901 | (12,582) | 21,307 | (12,459) | - | - | - | - | - | - | |
Medical Business | |||||||||||
科学事業 | 3,658 | (2,278) | 3,711 | (2,273) | - | - | - | - | - | - | |
Scientific Solutions Division | |||||||||||
映像事業 | 4,270 | (3,822) | 3,763 | (3,349) | - | - | - | - | - | - | |
Imaging Division | |||||||||||
その他、全社 | 6,345 | (2,889) | 6,174 | (2,835) | - | - | - | - | - | - | |
Others, Corporate | |||||||||||
*連結従業員数は正社員のみでパートは含まれておりません / The number of temporary employees is not included in the number of employees (consolidated). *( )は海外従業員数です / ():Number of overseas employees
2. セグメント別情報 / Information by Business Segment | |||||||||||
(1)医療事業 / Medical Business | |||||||||||
■ESD 損益 / Revenue and Operating profit of ESD | 百万円( million) | ||||||||||
項⽬ | FY2020 | FY2021 | |||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | |
売上⾼ | 95,410 | 111,379 | 108,334 | 110,620 | 425,742 | 79,198 | - | - | - | - | |
Revenue | |||||||||||
営業利益 | 21,918 | 37,898 | 31,762 | 17,843 | 109,424 | 14,631 | - | - | - | - | |
Operating profit | |||||||||||
その他の損益 | 188 | -445 | -379 | -1,217 | -1,852 | -362 | - | - | - | - | |
Other income and expenses | |||||||||||
営業利益率 | 23.0% | 34.0% | 29.3% | 16.1% | 25.7% | 18.5% | - | - | - | - | |
Operating profit margin | |||||||||||
売上⾼対前年⽐ | -17.0% | - | - | - | - | ||||||
Revenue (YoY) | |||||||||||
営業利益対前年⽐ | -33.2% | - | - | - | - | ||||||
Operating profit (YoY) | |||||||||||
■TSD 損益 / Revenue and Operating profit of TSD | 百万円( million) | ||||||||||
項⽬ | FY2020 | FY2021 | |||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | |
売上⾼ | 52,056 | 55,969 | 55,564 | 52,486 | 216,075 | 38,100 | - | - | - | - | |
Revenue | |||||||||||
営業利益 | 5,676 | 9,546 | 7,315 | 3,654 | 26,191 | 1,449 | - | - | - | - | |
Operating profit | |||||||||||
その他の損益 | -42 | -635 | -422 | -869 | -1,967 | -290 | - | - | - | - | |
Other income and expenses | |||||||||||
営業利益率 | 10.9% | 17.1% | 13.2% | 7.0% | 12.1% | 3.8% | - | - | - | - | |
Operating profit margin | |||||||||||
売上⾼対前年⽐ | -26.8% | - | - | - | - | ||||||
Revenue (YoY) | |||||||||||
営業利益対前年⽐ | -74.5% | - | - | - | - | ||||||
Operating profit (YoY) | |||||||||||
■医療事業 損益 / Revenue and Operating profit of Medical Business | 百万円( million) | ||||||||||
項⽬ | FY2020 | FY2021 | |||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | |
売上⾼ | 147,466 | 167,348 | 163,898 | 163,105 | 641,817 | 117,298 | - | - | - | - | |
Revenue | |||||||||||
営業利益 | 27,594 | 47,444 | 39,077 | 21,499 | 135,616 | 16,080 | - | - | - | - | |
Operating profit | |||||||||||
その他の損益 | 146 | -1,080 | -801 | -2,084 | -3,818 | -652 | - | - | - | - | |
Other income and expenses | |||||||||||
営業利益率 | 18.7% | 28.4% | 23.8% | 13.2% | 21.1% | 13.7% | - | - | - | - | |
Operating profit margin | |||||||||||
売上⾼対前年⽐ | -20.5% | - | - | - | - | ||||||
Revenue (YoY) | |||||||||||
営業利益対前年⽐ | -41.7% | - | - | - | - | ||||||
Operating profit (YoY) | |||||||||||
■ESD 投資他 / Expenditures etc of ESD | 百万円( million) | ||||||||||
項⽬ | FY2020 | FY2021 | |||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | |
減価償却費 | 8,507 | 7,657 | 8,728 | 9,347 | 34,239 | 8,361 | - | - | - | - | |
Depreciation and amortization | |||||||||||
資本的⽀出 | 8,544 | 11,365 | 10,126 | 17,522 | 47,557 | 8,308 | - | - | - | - | |
Capital expenditures | |||||||||||
研究開発⽀出 | 10,322 | 10,372 | 10,639 | 10,814 | 42,147 | 7,142 | - | - | - | - | |
R&D expenditures | |||||||||||
■TSD 投資他 / Expenditures etc of TSD | 百万円( million) | ||||||||||
項⽬ | FY2020 | FY2021 | |||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | |
減価償却費 | 4,581 | 4,665 | 4,589 | 4,227 | 18,062 | 3,081 | - | - | - | - | |
Depreciation and amortization | |||||||||||
資本的⽀出 | 2,101 | 3,024 | 3,357 | 4,415 | 12,897 | 2,182 | - | - | - | - | |
Capital expenditures | |||||||||||
研究開発⽀出 | 3,518 | 4,627 | 4,330 | 5,363 | 17,838 | 3,954 | - | - | - | - | |
R&D expenditures | |||||||||||
■医療事業 投資他 / Expenditures etc of Medical Business | 百万円( million) | ||||||||||
項⽬ | FY2020 | FY2021 | |||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | |
減価償却費 | 13,088 | 12,322 | 13,317 | 13,574 | 52,301 | 11,442 | - | - | - | - | |
Depreciation and amortization | |||||||||||
資本的⽀出 | 10,645 | 14,389 | 13,483 | 21,937 | 60,454 | 10,490 | - | - | - | - | |
Capital expenditures | |||||||||||
研究開発⽀出 | 13,840 | 14,999 | 14,969 | 16,177 | 59,985 | 11,096 | - | - | - | - | |
R&D expenditures | |||||||||||
2. セグメント別情報 / Information by Business Segment | ||||||||||||
(1)医療事業 / Medical Business | ||||||||||||
■ESD 地域別売上⾼ / Revenue by Region of ESD | 百万円( million) | |||||||||||
項⽬ | FY2020 | FY2021 | ||||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | ||
⽇本 | 14,500 | 19,454 | 12,724 | 18,779 | 65,457 | 9,912 | - | - | - | - | ||
Japan | ||||||||||||
北⽶ | 34,272 | 36,368 | 38,357 | 38,427 | 147,424 | 27,520 | - | - | - | - | ||
North America | ||||||||||||
欧州 | 22,074 | 23,707 | 27,703 | 27,757 | 101,241 | 20,198 | - | - | - | - | ||
Europe | ||||||||||||
中国 | 13,808 | 20,139 | 17,943 | 13,725 | 65,615 | 13,523 | - | - | - | - | ||
China | ||||||||||||
アジア・オセアニア | 8,909 | 9,232 | 8,563 | 9,497 | 36,201 | 6,905 | - | - | - | - | ||
Asia and Oceania | ||||||||||||
その他 | 1,847 | 2,480 | 3,042 | 2,435 | 9,804 | 1,140 | - | - | - | - | ||
Others | ||||||||||||
合計 | 95,410 | 111,379 | 108,334 | 110,620 | 425,742 | 79,198 | - | - | - | - | ||
Total | ||||||||||||
■TSD 地域別売上⾼ / Revenue by Region of TSD | 百万円( million) | |||||||||||
項⽬ | FY2020 | FY2021 | ||||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | ||
⽇本 | 9,872 | 12,170 | 10,593 | 10,368 | 43,003 | 8,486 | - | - | - | - | ||
Japan | ||||||||||||
北⽶ | 19,624 | 20,535 | 21,143 | 19,484 | 80,786 | 12,247 | - | - | - | - | ||
North America | ||||||||||||
欧州 | 12,610 | 11,868 | 14,188 | 14,260 | 52,926 | 9,546 | - | - | - | - | ||
Europe | ||||||||||||
中国 | 4,812 | 5,917 | 4,750 | 3,689 | 19,168 | 4,054 | - | - | - | - | ||
China | ||||||||||||
アジア・オセアニア | 4,380 | 4,604 | 3,944 | 3,839 | 16,767 | 3,275 | - | - | - | - | ||
Asia and Oceania | ||||||||||||
その他 | 758 | 875 | 946 | 846 | 3,425 | 492 | - | - | - | - | ||
Others | ||||||||||||
合計 | 52,056 | 55,969 | 55,564 | 52,486 | 216,075 | 38,100 | - | - | - | - | ||
Total | ||||||||||||
■医療事業 地域別売上⾼ / Revenue by Region of Medical Business | 百万円( million) | |||||||||||
項⽬ | FY2020 | FY2021 | ||||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | ||
⽇本 | 24,372 | 31,624 | 23,317 | 29,147 | 108,460 | 18,398 | - | - | - | - | ||
Japan | ||||||||||||
北⽶ | 53,896 | 56,903 | 59,500 | 57,911 | 228,209 | 39,767 | - | - | - | - | ||
North America | ||||||||||||
欧州 | 34,684 | 35,575 | 41,891 | 42,017 | 154,167 | 29,744 | - | - | - | - | ||
Europe | ||||||||||||
中国 | 18,620 | 26,056 | 22,693 | 17,414 | 84,783 | 17,577 | - | - | - | - | ||
China | ||||||||||||
アジア・オセアニア | 13,289 | 13,836 | 12,507 | 13,334 | 52,968 | 10,180 | - | - | - | - | ||
Asia and Oceania | ||||||||||||
その他 | 2,605 | 3,355 | 3,988 | 3,281 | 13,229 | 1,632 | - | - | - | - | ||
Others | ||||||||||||
合計 | 147,466 | 167,348 | 163,898 | 163,104 | 641,817 | 117,298 | - | - | - | - | ||
Total | ||||||||||||
■現地通貨別成⻑率 / Growth Rate of Medical Segment on Constant Currency Basis | ||||||||||||
項⽬ | FY2020 | FY2021 | ||||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | ||
⽇本 | 1% | 10% | -16% | -8% | -3% | -32% | - | - | - | - | ||
Japan | ||||||||||||
北⽶ | 2% | -2% | 7% | -3% | 1% | -18% | - | - | - | - | ||
North America | ||||||||||||
欧州 | 2% | 6% | 11% | 6% | 6% | -3% | - | - | - | - | ||
ESD | Europe | |||||||||||
中国 | 23% | 37% | 52% | 1% | 28% | 3% | - | - | - | - | ||
China | ||||||||||||
アジア・オセアニア | 10% | 4% | 5% | 1% | 5% | -18% | - | - | - | - | ||
Asia and Oceania | ||||||||||||
分野計 | 5% | 8% | 10% | -1% | 5% | -14% | - | - | - | - | ||
Total | ||||||||||||
⽇本 | 4% | 15% | -4% | 3% | 4% | -14% | - | - | - | - | ||
Japan | ||||||||||||
北⽶ | 2% | 4% | 2% | -3% | 1% | -36% | - | - | - | - | ||
North America | ||||||||||||
欧州 | 5% | 7% | 8% | 5% | 6% | -20% | - | - | - | - | ||
TSD | Europe | |||||||||||
中国 | 9% | 20% | 8% | -18% | 5% | -11% | - | - | - | - | ||
China | ||||||||||||
アジア・オセアニア | 12% | 16% | -6% | -15% | 1% | -21% | - | - | - | - | ||
Asia and Oceania | ||||||||||||
分野計 | 5% | 9% | 2% | -2% | 4% | -24% | - | - | - | - | ||
Total | ||||||||||||
⽇本 | 2% | 12% | -11% | -4% | 0% | -25% | - | - | - | - | ||
Japan | ||||||||||||
北⽶ | 2% | 0% | 5% | -3% | 1% | -24% | - | - | - | - | ||
North America | ||||||||||||
医療事業 | 欧州 | 3% | 7% | 10% | 6% | 6% | -9% | - | - | - | - | |
Europe | ||||||||||||
Medical | ||||||||||||
中国 | 19% | 32% | 40% | -4% | 22% | 0% | - | - | - | - | ||
Business | ||||||||||||
China | ||||||||||||
アジア・オセアニア | 11% | 8% | 1% | -4% | 4% | -19% | - | - | - | - | ||
Asia and Oceania | ||||||||||||
分野計 | 5% | 9% | 7% | -2% | 5% | -17% | - | - | - | - | ||
Total | ||||||||||||
2. セグメント別情報 / Information by Business Segment | |||||||||||||
(2)科学事業 / Scientific Solutions Division | |||||||||||||
■損益 / Revenue and Operating profit | 百万円( million) | ||||||||||||
項⽬ | FY2020 | FY2021 | |||||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | |||
売上⾼ | 22,613 | 27,126 | 26,897 | 28,552 | 105,189 | 17,757 | - | - | - | - | |||
Revenue | |||||||||||||
営業損益 | 1,644 | 3,735 | 2,629 | 1,989 | 9,997 | -1,604 | - | - | - | - | |||
Operating profit (losses) | |||||||||||||
その他の損益 | -162 | -76 | -213 | -99 | -549 | -313 | - | - | - | - | |||
Other income and expenses | |||||||||||||
営業利益率 | 7.3% | 13.8% | 9.8% | 7.0% | 9.5% | -9.0% | - | - | - | - | |||
Operating profit margin | |||||||||||||
売上⾼対前年⽐ | -21.5% | - | - | - | - | ||||||||
Revenue (YoY) | |||||||||||||
営業利益対前年⽐ | - | - | - | - | - | ||||||||
Operating profit (YoY) | |||||||||||||
■投資他 / Expenditures etc | 百万円( million) | ||||||||||||
項⽬ | FY2020 | FY2021 | |||||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | |||
減価償却費 | 1,782 | 1,780 | 1,818 | 2,258 | 7,638 | 1,699 | - | - | - | - | |||
Depreciation and amortization | |||||||||||||
資本的⽀出 | 1,681 | 1,688 | 1,001 | 2,057 | 6,427 | 1,367 | - | - | - | - | |||
Capital expenditures | |||||||||||||
研究開発⽀出 | 1,444 | 1,968 | 1,271 | 2,892 | 7,575 | 1,738 | - | - | - | - | |||
R&D expenditures | |||||||||||||
■地域別売上⾼ / Revenue by Region | 百万円( million) | ||||||||||||
項⽬ | FY2020 | FY2021 | |||||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | |||
⽇本 | 2,335 | 4,910 | 2,716 | 6,347 | 16,308 | 2,061 | - | - | - | - | |||
Japan | |||||||||||||
北⽶ | 7,251 | 7,828 | 8,449 | 7,839 | 31,367 | 4,592 | - | - | - | - | |||
North America | |||||||||||||
欧州 | 4,545 | 4,618 | 6,220 | 5,700 | 21,083 | 3,178 | - | - | - | - | |||
Europe | |||||||||||||
中国 | 3,969 | 4,912 | 4,523 | 3,622 | 17,026 | 4,353 | - | - | - | - | |||
China | |||||||||||||
アジア・オセアニア | 3,199 | 3,717 | 3,355 | 3,371 | 13,642 | 2,724 | - | - | - | - | |||
Asia and Oceania | |||||||||||||
その他 | 1,314 | 1,141 | 1,634 | 1,674 | 5,763 | 849 | - | - | - | - | |||
Others | |||||||||||||
合計 | 22,613 | 27,126 | 26,897 | 28,552 | 105,189 | 17,757 | - | - | - | - | |||
Total | |||||||||||||
2. セグメント別情報 / Information by Business Segment | |||||||||||
(3)映像事業 / Imaging Division | |||||||||||
■損益 / Revenue and Operating profit | 百万円( million) | ||||||||||
項⽬ | FY2020 | FY2021 | |||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | |
売上⾼ | 10,189 | 11,113 | 13,445 | 8,868 | 43,615 | 6,024 | - | - | - | - | |
Revenue | |||||||||||
営業損益 | -2,341 | -3,356 | -1,680 | -3,017 | -10,393 | -2,746 | - | - | - | - | |
Operating profit (losses) | |||||||||||
その他の損益 | -515 | -532 | -345 | -218 | -1,608 | -226 | - | - | - | - | |
Other income and expenses | |||||||||||
営業利益率 | - | - | - | - | - | - | - | - | - | - | |
Operating profit margin | |||||||||||
売上⾼対前年⽐ | -40.9% | - | - | - | - | ||||||
Revenue (YoY) | |||||||||||
営業利益対前年⽐ | - | - | - | - | - | ||||||
Operating profit (YoY) | |||||||||||
■投資他 / Expenditures etc | 百万円( million) | ||||||||||
項⽬ | FY2020 | FY2021 | |||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | |
減価償却費 | 413 | 416 | 449 | 225 | 1,503 | 237 | - | - | - | - | |
Depreciation and amortization | |||||||||||
資本的⽀出 | 819 | 1,001 | 548 | 677 | 3,045 | 483 | - | - | - | - | |
Capital expenditures | |||||||||||
研究開発⽀出 | 850 | 1,360 | 930 | 699 | 3,839 | 823 | - | - | - | - | |
R&D expenditures | |||||||||||
■地域別売上⾼ / Revenue by Region | 百万円( million) | ||||||||||
項⽬ | FY2020 | FY2021 | |||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | |
⽇本 | 2,910 | 3,753 | 3,931 | 2,748 | 13,342 | 1,287 | - | - | - | - | |
Japan | |||||||||||
北⽶ | 1,596 | 1,730 | 2,059 | 1,565 | 6,950 | 960 | - | - | - | - | |
North America | |||||||||||
欧州 | 3,902 | 3,628 | 5,035 | 3,395 | 15,960 | 2,991 | - | - | - | - | |
Europe | |||||||||||
中国 | 361 | 311 | 363 | 175 | 1,210 | 280 | - | - | - | - | |
China | |||||||||||
アジア・オセアニア | 1,367 | 1,648 | 1,993 | 943 | 5,951 | 449 | - | - | - | - | |
Asia and Oceania | |||||||||||
その他 | 53 | 43 | 64 | 42 | 202 | 57 | - | - | - | - | |
Others | |||||||||||
合計 | 10,189 | 11,113 | 13,445 | 8,868 | 43,615 | 6,024 | - | - | - | - | |
Total | |||||||||||
■デジタルカメラデータ / Revenue & Unit sales of Digital camera | |||||||||||
項⽬ | FY2020 | FY2021 | |||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | |
ミラーレス⼀眼 | 77 | 76 | 107 | 64 | 324 | 48 | - | - | - | - | |
売上⾼ | Digital SLR | ||||||||||
コンパクト | |||||||||||
(億円) | 12 | 23 | 15 | 12 | 62 | 6 | - | - | - | - | |
Compact | |||||||||||
Revenue | |||||||||||
その他 | 13 | 12 | 12 | 12 | 49 | 7 | - | - | - | - | |
(100 | |||||||||||
Others | |||||||||||
million) | |||||||||||
合計 | 102 | 111 | 134 | 89 | 436 | 60 | - | - | - | - | |
Total | |||||||||||
出荷台数 | ミラーレス⼀眼 | 7 | 8 | 11 | 6 | 31 | 5 | - | - | - | - |
Digital SLR | |||||||||||
(万台) | |||||||||||
コンパクト | |||||||||||
Unit sales | 3 | 6 | 4 | 4 | 18 | 2 | - | - | - | - | |
(ten | Compact | ||||||||||
合計 | 11 | 14 | 15 | 10 | 49 | 6 | - | - | - | - | |
thousands) | |||||||||||
Total |
2. セグメント別情報 / Information by Business Segment | |||||||||||||
(4)その他 / Others | |||||||||||||
■損益 / Revenue and Operating profit | 百万円( million) | ||||||||||||
項⽬ | FY2020 | FY2021 | |||||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | |||
売上⾼ | 1,617 | 1,717 | 1,642 | 1,814 | 6,790 | 1,324 | - | - | - | - | |||
Revenue | |||||||||||||
営業損益 | -646 | -663 | -517 | -917 | -2,744 | -438 | - | - | - | - | |||
Operating profit (losses) | |||||||||||||
その他の損益 | 1 | -2 | 3 | -51 | -54 | 2 | - | - | - | - | |||
Other income and expenses | |||||||||||||
営業利益率 | - | - | - | - | - | - | - | - | - | - | |||
Operating profit margin | |||||||||||||
売上⾼対前年⽐ | -18.1% | - | - | - | - | ||||||||
Revenue (YoY) | |||||||||||||
営業利益対前年⽐ | - | - | - | - | - | ||||||||
Operating profit (YoY) | |||||||||||||
■地域別売上⾼ / Revenue by Region | 百万円( million) | ||||||||||||
項⽬ | FY2020 | FY2021 | |||||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | |||
⽇本 | 1,475 | 1,593 | 1,537 | 1,703 | 6,308 | 1,233 | - | - | - | - | |||
Japan | |||||||||||||
北⽶ | 58 | 47 | 34 | 38 | 177 | 24 | - | - | - | - | |||
North America | |||||||||||||
欧州 | 22 | 21 | 11 | 12 | 66 | 13 | - | - | - | - | |||
Europe | |||||||||||||
中国 | 4 | 1 | 2 | 10 | 17 | 2 | - | - | - | - | |||
China | |||||||||||||
アジア・オセアニア | 58 | 56 | 57 | 50 | 221 | 52 | - | - | - | - | |||
Asia and Oceania | |||||||||||||
その他 | - | - | - | - | - | - | - | - | - | - | |||
Others | |||||||||||||
合計 | 1,617 | 1,717 | 1,642 | 1,814 | 6,790 | 1,324 | - | - | - | - | |||
Total | |||||||||||||
(5)全社消去 / Corporate expenses | |||||||||||||
■損益 / Revenue and Operating profit | 百万円( million) | ||||||||||||
項⽬ | FY2020 | FY2021 | |||||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | |||
売上⾼ | - | - | - | - | - | - | - | - | - | - | |||
Revenue | |||||||||||||
営業損益 | -11,515 | -10,959 | -11,964 | -14,468 | -49,006 | -10,102 | - | - | - | - | |||
Operating profit (losses) | |||||||||||||
その他の損益 | -462 | -490 | -1,885 | -2,594 | -5,531 | -269 | - | - | - | - | |||
Other income and expenses | |||||||||||||
■投資他 (その他・全社消去) / Expenditures etc(Others, Corporate expenses) | 百万円( million) | ||||||||||||
項⽬ | FY2020 | FY2021 | |||||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total | |||
減価償却費 | 2,145 | 1,452 | 1,542 | 1,728 | 6,867 | 2,000 | - | - | - | - | |||
Depreciation and amortization | |||||||||||||
資本的⽀出 | 1,478 | 1,158 | 1,901 | 2,721 | 7,258 | 3,019 | - | - | - | - | |||
Capital expenditures | |||||||||||||
研究開発⽀出 | 5,061 | 5,297 | 4,987 | 4,845 | 20,190 | 5,037 | - | - | - | - | |||
R&D expenditures | |||||||||||||
3. 連結財政状態計算書 / Statement of financial position
百万円( million) | ||||||||
項⽬ | FY2020 | FY2021 | ||||||
Item | As of | As of | As of | As of | As of | As of | As of | As of |
Jun 30 | Sep 30 | Dec 31 | Mar 31 | Jun 30 | Sep 30 | Dec 31 | Mar 31 | |
資産 | 938,295 | 961,871 | 987,915 | 1,015,663 | 1,099,081 | - | - | - |
Assets | ||||||||
流動資産 | 441,922 | 464,363 | 483,639 | 506,707 | 604,400 | - | - | - |
Current assets | ||||||||
現⾦及び現⾦同等物 | 113,261 | 135,216 | 144,697 | 162,494 | 270,506 | - | - | - |
Cash and cash equivalents | ||||||||
棚卸資産 | 162,434 | 162,378 | 167,858 | 167,596 | 183,318 | - | - | - |
Inventories | ||||||||
その他 | 166,227 | 166,769 | 171,084 | 176,617 | 150,576 | - | - | - |
Others | ||||||||
⾮流動資産 | 496,373 | 497,508 | 504,276 | 508,956 | 494,681 | - | - | - |
Non-current assets | ||||||||
負債 | 507,106 | 599,020 | 590,646 | 643,705 | 737,126 | - | - | - |
Liabilities | ||||||||
流動負債 | 285,722 | 378,144 | 281,506 | 333,770 | 344,410 | - | - | - |
Current liabilities | ||||||||
⾮流動負債 | 221,384 | 220,876 | 309,140 | 309,935 | 392,716 | - | - | - |
Non-current liabilities | ||||||||
資本 | 431,189 | 362,851 | 397,269 | 371,958 | 361,955 | - | - | - |
Equity | ||||||||
親会社の所有者に帰属する持分 | ||||||||
Total equity attributable to owners | 429,956 | 361,624 | 396,039 | 370,747 | 360,910 | - | - | - |
of parent | ||||||||
その他 | 1,233 | 1,227 | 1,230 | 1,211 | 1,045 | - | - | - |
Others | ||||||||
有利⼦負債 | 181,546 | 281,588 | 267,122 | 280,915 | 395,920 | - | - | - |
Interest-bearing debt | ||||||||
純有利⼦負債 | 68,285 | 146,372 | 122,425 | 118,421 | 125,414 | - | - | - |
Net debt | ||||||||
⾃⼰資本⽐率 | 45.8% | 37.6% | 40.1% | 36.5% | 32.8% | - | - | - |
Equity ratio | ||||||||
4. キャッシュ・フロー計算書 / Statement of cash flows
百万円( million)
項⽬ | FY2020 | FY2021 | ||||||||
Item | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total |
営業キャッシュ・フロー | 28,406 | 38,864 | 38,466 | 27,808 | 133,544 | 8,388 | - | - | - | - |
Cash flows from operating activities | ||||||||||
投資キャッシュ・フロー | -15,513 | -15,900 | -13,624 | -17,393 | -62,430 | -12,291 | - | - | - | - |
Cash flows from investing activities | ||||||||||
フリー・キャッシュ・フロー | 12,893 | 22,964 | 24,842 | 10,415 | 71,114 | -3,903 | - | - | - | - |
Free cash flows | ||||||||||
財務キャッシュ・フロー | -11,285 | 758 | -18,433 | 9,498 | -19,462 | 111,818 | - | - | - | - |
Cash flows from financing activities | ||||||||||
5. 指標 / Financial Indicators
百万円( million) | ||||||
項⽬ | FY2017 | FY2018 | FY2019 | FY2020 | ||
Item | ||||||
売上⾼ | 740,557 | 786,497 | 793,862 | 797,411 | ||
Revenue | ||||||
内視鏡事業 | - | - | 418,833 | 425,742 | ||
ESD | ||||||
治療機器事業 | - | - | 215,468 | 216,075 | ||
TSD | ||||||
医療事業 | 570,398 | 616,331 | 634,301 | 641,817 | ||
Medical Business | ||||||
科学事業 | 93,370 | 100,016 | 104,225 | 105,189 | ||
Scientic Solutions Division | ||||||
映像事業 | 62,824 | 60,298 | 48,679 | 43,615 | ||
Imaging Division | ||||||
その他 | 13,965 | 9,852 | 6,657 | 6,790 | ||
Others | ||||||
営業利益 | 71,192 | 81,029 | 28,281 | 83,469 | ||
Operating profit | ||||||
内視鏡事業 | - | - | 89,771 | 109,424 | ||
ESD | ||||||
治療機器事業 | - | - | 22,163 | 26,191 | ||
TSD | ||||||
医療事業 | 114,703 | 121,784 | 111,934 | 135,616 | ||
Medical Business | ||||||
科学事業 | 5,927 | 6,425 | 8,135 | 9,997 | ||
Scientic Solutions Division | ||||||
映像事業 | 153 | -1,200 | -18,268 | -10,393 | ||
Imaging Division | ||||||
その他 | -1,138 | -4,966 | -3,521 | -2,744 | ||
Others | ||||||
全社・消去 | -48,453 | -41,014 | -69,999 | -49,006 | ||
Elimination or Corporate | ||||||
法⼈所得税費⽤ | 19,671 | 19,573 | 12,068 | 26,143 | ||
Income taxes | ||||||
親会社の所有者に帰属する当期利益 | 42,783 | 57,064 | 8,147 | 51,670 | ||
Profit attributable to owners of parent | ||||||
FY2023 target | ||||||
営業利益率 | 9.6% | 10.3% | 3.6% | 10.5% | 20%以上/ Over 20% | |
Operating profit margin | ||||||
フリー・キャッシュフロー | 81,238 | 41,834 | 6,647 | 71,114 | CAGR 20%以上 / | |
Free cash flows | Over 20%** | |||||
1株当たり当期利益(円)* | 31.25 | 41.71 | 5.97 | 39.37 | CAGR 25%以上 / | |
Earnings per share [Yen] | Over 25%** | |||||
総資産 | 960,032 | 978,663 | 932,030 | 1,015,663 | ||
Total assets | ||||||
有利⼦負債 | 285,970 | 247,974 | 181,335 | 280,915 | ||
Interest-bearing debt | ||||||
資本 | 396,228 | 444,259 | 442,387 | 371,958 | ||
Total equity | ||||||
親会社所有者帰属持分 | 394,751 | 442,793 | 441,193 | 370,747 | ||
Equity Attributable to Owners of Parent | ||||||
1株当たり親会社所有者帰属持分(円)* | 288.36 | 324.25 | 323.06 | 288.39 | ||
Equity attributable to owners of parent per share [Yen] | ||||||
1株当たり配当(円) | 28 | 28 | 30 | 10* | ||
Cash dividends per share [Yen] | ||||||
連結総還元性向 | 22.4% | 23.2% | 125.7% | 205.6% | ||
Consolidated total return ratio | ||||||
親会社の所有者に帰属する当期利益率 | 5.8% | 7.3% | 1.0% | 6.5% | ||
Profit attributable to owners of parent margin | ||||||
減価償却費 | 52,853 | 52,913 | 58,669 | 68,309 | ||
Depreciation and amortization | ||||||
資本的⽀出 | 60,683 | 65,255 | 66,830 | 77,184 | ||
Capital expenditures | ||||||
研究開発⽀出 | 79,178 | 89,470 | 93,968 | 91,589 | ||
R&D expenditures | ||||||
開発費資産化 | 5,878 | 10,228 | 9,398 | 23,004 | ||
Capitalization of R&D expenditures | ||||||
円/USD(期中平均レート) | 108.38 | 110.85 | 110.91 | 108.74 | ||
Yen / U.S. dollar (Average rate) | ||||||
円/EUR(期中平均レート) | 118.79 | 129.70 | 128.41 | 120.82 | ||
Yen / Euro (Average rate) | ||||||
16.11 16.75 16.54 15.60
*当社は2019年4⽉1⽇付で普通株式1株につき4株の割合で株式分割を⾏っており、株式分割後の数字を表⽰しています。 /
On April 1, 2019, the Company conducted a four-for-one stock split of common stock and these figures are after the stock split. **FY2020以降。特殊要因調整後 / From FY2020. Adjusted for extraordinary items
6.会社概要 / Corporate Outline
■会社概要 / Corporate outline | 2020年3⽉31⽇現在 | |
As of Mar 31, 2020 | ||
会社名 | オリンパス株式会社 | |
Company name | Olympus Corporation | |
上場市場 | 東証⼀部 | |
Market | 1st section of Tokyo Stock Exchange | |
銘柄コード | 7733 | |
Stock code | ISIN: JP3201200007 | |
設⽴年⽉⽇ | 1919年10⽉12⽇ | |
Established | October 12, 1919 | |
資本⾦(百万円) | 124,643 | |
Capital ( million) | ||
連結従業員数 | 35,174 | |
Consolidated headcount | ||
グループ会社数 | 92(本社除く / excluding Olympus Corporation) | |
Number of group companies | ||
〒163-0914 東京都新宿区⻄新宿2丁⽬3番1号 新宿モノリス | ||
本社 | https://www.olympus.co.jp/ | |
Head Office | Shinjuku Monolith, 3-1Nishi-Shinjuku2-chome,Shinjuku-ku, Tokyo 163-0914, Japan | |
https://www.olympus-global.com/network/ | ||
事業場 | ⼋王⼦市(東京都)、上伊那郡(⻑野県)、⻄⽩河郡(福島県) | |
Factroy, R&D Center | Hachioji Tokyo Met., Kami Ina Nagano Pref., Nishi Shirakawa Fukushima Pref. | |
⽀店 | 札幌、名古屋、⼤阪、広島、福岡 | |
Branch Offices | Sapporo, Nagoya, Osaka, Hiroshima, Fukuoka | |
営業所 | 新潟、松本、静岡、⾦沢、京都、岡⼭、松⼭、⿅児島 | |
Sales Offices | Niigata, Matsumoto, Shizuoka, Kanazawa, Kyoto, Okayama, Matsuyama, Kagoshima | |
海外拠点 | アメリカ、ドイツ、イギリス、中国、シンガポールほか | |
Overseas Offices | USA, Germany, UK, China, Singapore etc | |
■株式状況 / Stock information | 2020年3⽉31⽇現在 | |
As of Mar 31, 2020 | ||
発⾏可能株式総数(株) | 4,000,000,000 | |
Total Number of Authorized Shares | ||
発⾏済株式総数(株) | 1,370,914,963 | |
Number of Shares Issued (Shares) | ||
■株式の分布状況 / Shareholder Distribution | 2020年3⽉31⽇現在 | |
As of Mar 31, 2020 | ||
所有株式数 | 所有株式数の割合 | |
Number of shares | Shareholders ratio | |
⾦融機関 | 549,633,760 | 40.1% |
Japanese financial institution | ||
証券会社 | 13,921,827 | 1.0% |
Japanese securities firms | ||
その他国内法⼈ | 44,340,745 | 3.2% |
Other Japanese corporations | ||
外国⼈ | 619,096,143 | 45.2% |
Foreign institutions and individuals | ||
個⼈・その他 | 58,592,708 | 4.3% |
Jananese individuals and others | ||
⾃⼰株式 | 85,329,780 | 6.2% |
Treasury stock | ||
合計 | 1,370,914,963 | 100.0% |
Total | ||
7.オリンパスの医療事業 / Medical Business of Olympus
7.オリンパスの医療事業 / Medical Business of Olympus
Attachments
- Original document
- Permalink
Disclaimer
Olympus Corporation published this content on 05 August 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 August 2020 06:06:10 UTC